Top scientists from eight companies discuss what it takes to maintain a creative and productive laboratory environment
Just five years later, however - after spending $5 million - Calgene plant pathologist Robert Goodman made a tough call: He decided to abort the whole project.
"It wasn't an easy decision to make," says Goodman, who until this summer was Calgene's vice president for research and development. "It was a good commercial opportunity, but we were unable to bring the technology on line fast enough. There were other projects that were closer to market and more certain commercially."
Interested in reading more?
Become a Member of
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member?